Medtronic (MDT) Stock Forecast & Price Target

Compare

6,340 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MDT Analyst Ratings

Moderate Buy

10 Buy

10 Hold

0 Sell

Based on 20 analysts giving stock ratings to

Medtronic

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MDT Stock 12 Month Forecast

Average Price Target

$111.41

▲(14.30% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Medtronic in the last 3 months. The average price target is $111.41 with a high forecast of $120.00 and a low forecast of $102.00. The average price target represents a 14.30% change from the last price of $97.47.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"77":"$77","88":"$88","99":"$99","110":"$110","121":"$121"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":111.41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$111.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":102,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$102.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[77,88,99,110,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.34,104.62153846153846,105.90307692307692,107.18461538461538,108.46615384615384,109.7476923076923,111.02923076923076,112.31076923076924,113.5923076923077,114.87384615384616,116.15538461538462,117.43692307692308,118.71846153846154,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.34,103.96076923076923,104.58153846153846,105.2023076923077,105.82307692307693,106.44384615384615,107.06461538461538,107.68538461538462,108.30615384615385,108.92692307692307,109.5476923076923,110.16846153846154,110.78923076923077,{"y":111.41,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.34,103.23692307692308,103.13384615384615,103.03076923076924,102.92769230769231,102.82461538461538,102.72153846153846,102.61846153846155,102.51538461538462,102.41230769230769,102.30923076923077,102.20615384615385,102.10307692307693,{"y":102,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":83.78,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.01,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.69,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.86,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.1,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.42,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.08,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.63,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.81,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.34,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$120.00

Average Price Target$111.41

Lowest Price Target$102.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Brandon Vazquez

William Blair

Hold

―

Reiterated

12/22/25

Medtronic: Fairly Valued on Aligned EPS Guidance and Higher Interest Costs, Justifying a Hold RatingWe are updating our model ahead of year-end. Our revenue forecasts remain unchanged; however, we are adjusting our interest expense to be more in line with management’s guidance, which slightly decreased our EPS estimates. Our new non-GAAP EPS estimates are in line with management’s prior commentary and guidance. See below for a table of our changes.

Richard Newitter

Truist Financial

$110→$107

Hold

9.78%

Upside

Reiterated

12/18/25

Medtronic price target lowered to $107 from $110 at TruistMedtronic price target lowered to $107 from $110 at Truist

David Rescott

Robert W. Baird

$109→$103

Hold

5.67%

Upside

Reiterated

12/16/25

Robert W. Baird Remains a Hold on Medtronic (MDT)

Shagun Singh Chadha

RBC Capital

$118

Buy

21.06%

Upside

Reiterated

12/16/25

RBC Capital Sticks to Their Buy Rating for Medtronic (MDT)

Lee Hambright

Bernstein

$111

Buy

13.88%

Upside

Reiterated

12/12/25

Medtronic (MDT) Receives a Buy from Bernstein

Joanne Wuensch

Citi

$117

Buy

20.04%

Upside

Reiterated

12/11/25

Citi Keeps Their Buy Rating on Medtronic (MDT)

Matthew O'Brien

Piper Sandler

$105

Hold

7.73%

Upside

Reiterated

12/11/25

Piper Sandler Reaffirms Their Hold Rating on Medtronic (MDT)

Christopher Pasquale

Nephron

$120

Buy

23.11%

Upside

Upgraded

12/08/25

Medtronic upgraded to Buy from Hold at Nephron ResearchMedtronic upgraded to Buy from Hold at Nephron Research

Travis Steed

Bank of America Securities

$115

Buy

17.99%

Upside

Reiterated

12/04/25

Analysts Offer Insights on Healthcare Companies: Cooper Co (NASDAQ: COO) and Medtronic (NYSE: MDT)

Josh Jennings

TD Cowen

$119

Buy

22.09%

Upside

Reiterated

12/04/25

Medtronic's Strategic Advancements and Early FDA Approval of Hugo Boost Buy Rating

Rick Wise

Stifel Nicolaus

$105

Hold

7.73%

Upside

Assigned

12/03/25

Medtronic's Cautious U.S. Market Entry with HUGO: Hold Rating Amid Uncertain Impact

Ryan Zimmerman

BTIG

Hold

―

Reiterated

12/03/25

Medtronic's Strategic Moves and Market Position: Balancing Growth Prospects with Current Valuation

Matt Miksic

Barclays

$111

Buy

13.88%

Upside

Reiterated

11/20/25

Barclays Sticks to Its Buy Rating for Medtronic (MDT)

Robbie Marcus

J.P. Morgan

$100→$105

Hold

7.73%

Upside

Reiterated

11/19/25

J.P. Morgan Sticks to Their Hold Rating for Medtronic (MDT)

Danielle Antalffy

UBS

$95→$102

Hold

4.65%

Upside

Reiterated

11/19/25

Cautious Hold Rating on Medtronic Amid Mixed Segment Performance and Uncertain Growth Prospects

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Brandon Vazquez

William Blair

Hold

―

Reiterated

12/22/25

Richard Newitter

Truist Financial

$110→$107

Hold

9.78%

Upside

Reiterated

12/18/25

Medtronic price target lowered to $107 from $110 at TruistMedtronic price target lowered to $107 from $110 at Truist

David Rescott

Robert W. Baird

$109→$103

Hold

5.67%

Upside

Reiterated

12/16/25

Robert W. Baird Remains a Hold on Medtronic (MDT)

Shagun Singh Chadha

RBC Capital

$118

Buy

21.06%

Upside

Reiterated

12/16/25

RBC Capital Sticks to Their Buy Rating for Medtronic (MDT)

Lee Hambright

Bernstein

$111

Buy

13.88%

Upside

Reiterated

12/12/25

Medtronic (MDT) Receives a Buy from Bernstein

Joanne Wuensch

Citi

$117

Buy

20.04%

Upside

Reiterated

12/11/25

Citi Keeps Their Buy Rating on Medtronic (MDT)

Matthew O'Brien

Piper Sandler

$105

Hold

7.73%

Upside

Reiterated

12/11/25

Piper Sandler Reaffirms Their Hold Rating on Medtronic (MDT)

Christopher Pasquale

Nephron

$120

Buy

23.11%

Upside

Upgraded

12/08/25

Medtronic upgraded to Buy from Hold at Nephron ResearchMedtronic upgraded to Buy from Hold at Nephron Research

Travis Steed

Bank of America Securities

$115

Buy

17.99%

Upside

Reiterated

12/04/25

Analysts Offer Insights on Healthcare Companies: Cooper Co (NASDAQ: COO) and Medtronic (NYSE: MDT)

Josh Jennings

TD Cowen

$119

Buy

22.09%

Upside

Reiterated

12/04/25

Medtronic's Strategic Advancements and Early FDA Approval of Hugo Boost Buy Rating

Rick Wise

Stifel Nicolaus

$105

Hold

7.73%

Upside

Assigned

12/03/25

Medtronic's Cautious U.S. Market Entry with HUGO: Hold Rating Amid Uncertain Impact

Ryan Zimmerman

BTIG

Hold

―

Reiterated

12/03/25

Medtronic's Strategic Moves and Market Position: Balancing Growth Prospects with Current Valuation

Matt Miksic

Barclays

$111

Buy

13.88%

Upside

Reiterated

11/20/25

Barclays Sticks to Its Buy Rating for Medtronic (MDT)

Robbie Marcus

J.P. Morgan

$100→$105

Hold

7.73%

Upside

Reiterated

11/19/25

J.P. Morgan Sticks to Their Hold Rating for Medtronic (MDT)

Danielle Antalffy

UBS

$95→$102

Hold

4.65%

Upside

Reiterated

11/19/25

Cautious Hold Rating on Medtronic Amid Mixed Segment Performance and Uncertain Growth Prospects

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Medtronic

1 Month

xxx

Success Rate

16/27 ratings generated profit

Average Return

+0.71%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 59.26% of your transactions generating a profit, with an average return of +0.71% per trade.

3 Months

xxx

Success Rate

17/22 ratings generated profit

Average Return

+4.58%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 77.27% of your transactions generating a profit, with an average return of +4.58% per trade.

1 Year

Josh JenningsTD Cowen

Success Rate

23/27 ratings generated profit

Average Return

+7.57%

reiterated a buy rating 21 days ago

Copying Josh Jennings's trades and holding each position for 1 Year would result in 85.19% of your transactions generating a profit, with an average return of +7.57% per trade.

2 Years

xxx

Success Rate

26/29 ratings generated profit

Average Return

+13.53%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 89.66% of your transactions generating a profit, with an average return of +13.53% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MDT Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MDT has received 34 Buy Ratings, 23 Hold Ratings, and 0 Sell Ratings. MDT average Analyst price target in the past 3 months is 111.41.

Each month's total comprises the sum of three months' worth of ratings.

MDT Financial Forecast

MDT Earnings Forecast

Next quarter’s earnings estimate for MDT is $1.33 with a range of $1.33 to $1.35. The previous quarter’s EPS was $1.36. MDT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MDT has Performed in-line its overall industry.

MDT Sales Forecast

Next quarter’s sales forecast for MDT is $8.91B with a range of $8.86B to $9.04B. The previous quarter’s sales results were $8.96B. MDT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MDT has Performed in-line its overall industry.

MDT Stock Forecast FAQ

What is MDT’s average 12-month price target, according to analysts?

Based on analyst ratings, Medtronic’s 12-month average price target is 111.41.

What is MDT’s upside potential, based on the analysts’ average price target?

Medtronic has 14.30% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MDT a Buy, Sell or Hold?

Medtronic has a consensus rating of Moderate Buy which is based on 10 buy ratings, 10 hold ratings and 0 sell ratings.

What is Medtronic’s price target?

The average price target for Medtronic is 111.41. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $120.00 ,the lowest forecast is $102.00. The average price target represents 14.30% Increase from the current price of $97.47.

What do analysts say about Medtronic?

Medtronic’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of MDT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Medtronic (MDT) Stock Forecast & Price Target

MDT Analyst Ratings

MDT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Medtronic

MDT Analyst Recommendation Trends

MDT Financial Forecast

MDT Earnings Forecast

MDT Sales Forecast

MDT Stock Forecast FAQ

Detailed List of Analyst Forecasts